Statins has been studied in 2,082 papers since 1993: 207 trials and 920 observational studies in people, 195 in animals, 67 in cells, 578 reviews; 1,010 in the past year. The newest story, Nov 18, 2026: “Statins not linked to lower dementia risk in older male veterans”.
Statin use is linked with lower mortality in critically ill stroke patients, while independent labs reproduce simvastatin lifespan extension in flies and reduced senescence with pravastatin in human cells. A contrasting result shows simvastatin shortens fly lifespan. Some papers declare ties to developers, and some authors work at companies.
2,397 findings in 1,205 papers from 1993 to 2026, 243 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 545 independent labs in 68 countries; 1,470 trials, 270 about aging, 746 with no results posted.
“Statins across intensities and statin–ezetimibe therapy were not associated with increased overall or site-specific cancer risk.”
Cells, worms or flies, mice and humans: replicated by independent labs.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
545 independent labs in 68 countries
267 findings against
1,470 trials, 270 about aging, 746 with no results posted
DrugAge records 7 results from 4 papers: 5 in C. elegans, 1 in B. manjavacas and 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·
Statins were not clearly linked with mortality in humans (multivariable adjusted analysis in severe traumatic brain injury).
“After adjusting for baseline differences, pre-injury statin use was not an independent predictor of mortality following multiple logistic regression.”
Humansmultivariable adjusted analysis in severe traumatic brain injuryn = 816
“Both SIM concentrations (0.1 and 1 μM) significantly reduced the basal expression of these inflammatory cytokines compared to that in the control group (p < 0.001).”
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·
Atorvastatin is linked with lower LDL-C in humans (dyslipidemia) (-54.55%).
“In 55 patients who completed follow-up, a decrease in LDL-C, total cholesterol, triglycerides, and ApoE was 54.55%, 40.60%, 53.1%, and 40.46%, respectively.”
“Intensive lipid lowering remains key, with high-intensity statins, ezetimibe, and PCSK9 inhibitors used sequentially to achieve very low LDL-C targets”
Statins are linked with lower LDL cholesterol in humans (around the first recorded prescription date) (donut estimates vary from - 1.00 to - 1.72 mmol/L).
“Statin analyses show a local downward LDL discontinuity around the first recorded prescription date”
↑upin rats2↔no changein F. catus1↑upin human cells1↓downin human cells1+1+65%
6 studies
Simvastatin activates angiogenesis in human cells (SHED-HUVEC co-culture).
“Simvastatin also elevated the expression of angiogenic regulatory factors in SHED, promoting more extensive reticular structure formation by HUVEC through paracrine interactions between SHED and HUVEC.”
Rosuvastatin decreases C-reactive protein in humans (Compared with atorvastatin after excluding one outlying study) (MD −0.16 mg/L; 95% CI −0.28 to −0.03; p = 0.01).
“rosuvastatin demonstrated a greater CRP reduction (MD –0.16 mg/L; 95% CI –0.28 to –0.03; p = 0.01)”
ReviewCompared with atorvastatin after excluding one outlying study
Statins decrease C-reactive protein in humans (parallel controlled trials) (SMD -1.45, 95% CI -2.84 to -0.07).
“Statins lowered CRP in both controlled before-after studies (standardised mean difference (SMD)=-0.38, 95% CI -0.73 to -0.03; p=0.032) and parallel controlled trials (SMD=-1.45, 95% CI -2.84 to -0.07; p=0.040).”
Pitavastatin decreases major adverse cardiovascular events in humans (people living with HIV receiving antiretroviral therapy) (approximately 35% reduction).
“pitavastatin therapy reduced major adverse cardiovascular events by approximately 35% in people living with HIV receiving antiretroviral therapy”
Reviewpeople living with HIV receiving antiretroviral therapy
Statins are linked with rhabdomyolysis in humans (CK of 23,203 U/L).
“Here, we report the case of a 77-year-old woman who presented with myalgias and weakness and was subsequently found to have a CK of 23,203 U/L, transaminitis, and acute kidney injury”
Atorvastatin showed no clear effect on total cholesterol in humans (compared with placebo, fully adjusted model).
“atorvastatin did not improve frailty status, frailty-related components, total cholesterol, or serum myostatin levels compared with placebo in PLHIV receiving ART”
Human trialcompared with placebo, fully adjusted model40 mg once daily12 weeks
“Statins remain the mainstay of pharmacotherapy for reducing concentrations of total cholesterol and low-density lipoproteins, as well as for preventing atherosclerotic cardiovascular disease.”
Statins showed no clear effect on cancer-related mortality in humans (moderate-intensity vs high-intensity statin therapy) (RR 1.1 (95% CrI 0.94–1.2)).
“Compared with high-intensity statin therapy, RRs were 1.1 (95% CrI 0.94–1.2) for moderate-intensity”
Human trialmoderate-intensity vs high-intensity statin therapyn = 203,995
Statins were not clearly linked with cancer-related mortality in humans (without CHD).
“Statin use was associated with lower all-cause, cardiac, and cancer-related mortality in older cancer survivors with CHD, but not with cancer-related mortality in those without CHD.”
Atorvastatin showed no clear effect on adverse events in humans.
“No clinically significant differences in adverse events were observed.”
Human trialAdded to standard triple therapy versus standard triple therapy with placebo in patients with H. pylori infection40 mg once daily14 daysn = 138
Research in heart yield and translational medicine·
Rosuvastatin was not clearly linked with major adverse cardiovascular events in humans (primary biliary cholangitis) (HR, 0.870 [95% CI, 0.740–1.023]; p = 0.091).
Statins are associated with mortality in humans (Newly diagnosed heart failure; baseline CRP <2 mg/L; compared with statin nonusers) (HR 0.45, 95% CI 0.41–0.50).
“Statin therapy was also associated with lower all-cause mortality in both CRP strata”
HumansNewly diagnosed heart failure; baseline CRP <2 mg/L; compared with statin nonusers≥90 consecutive days after HF diagnosis
Statins are linked with a lower risk of mortality in humans (non-ischemic acute myocardial injury) (HR 0.79, 95% CI 0.75–0.84).
“In fully adjusted models, statin use was independently associated with lower 1-year all-cause mortality in both cohorts (development: HR 0.79, 95% CI 0.75–0.84”
Statins are associated with mortality in humans (Patients with CKD G5D following an ASCVD event; statin initiators versus non-initiators) (At four years: risk difference -6.2% (95% CI -10.2 to -2.2), relative risk 0.88 (95% CI 0.81–0.96); mean survival gain 69 days at five years (95% CI 14–125) and 135 days at ten years (95% CI 31–239)).
“During the ten years of follow-up, statin use was associated with a reduced risk of mortality.”
HumansPatients with CKD G5D following an ASCVD event; statin initiators versus non-initiatorsTen years67% malesn = 5,534
Rosuvastatin is associated with major adverse cardiovascular events in humans (ACS and multivessel coronary disease; compared with atorvastatin) (RR 1.21, 95% CI 0.79–1.85; P = 0.372).
“rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79–1.85; P = 0.372)”
HumansACS and multivessel coronary disease; compared with atorvastatin3 monthsn = 277
Statins are associated with major adverse cardiovascular events in humans (Adherent patients with uncomplicated hypertension; per-protocol sensitivity analysis) (HR 0.28, 95% CI 0.11–0.70).
“adherence to renin-angiotensin system inhibitors and statins was associated with significantly lower risk of MACE”
HumansAdherent patients with uncomplicated hypertension; per-protocol sensitivity analysisMedian follow-up of 52 months
Rosuvastatin is associated with major adverse cardiovascular events in humans (HR 0.84, 95% CI 0.76–0.93; 624 versus 769 events).
“rosuvastatin was associated with a lower major adverse cardiovascular events rate than atorvastatin (624 versus 769 events; hazard ratio [HR], 0.84 [95% CI, 0.76-0.93]).”
HumansPatients with cancer receiving tyrosine kinase inhibitors; comparison with atorvastatin; time-averaged association because proportional hazards were violatedDay 30 to up to 3 years
Statins are linked with a lower risk of major adverse cardiovascular events in new-onset T2D (HR 0.41, 95% CI 0.21-0.83).
“statin therapy was independently associated with a lower MACE risk according to the multivariable Cox regression analysis (HR 0.41, 95% CI 0.21-0.83; p = 0.013)”
Statins are linked with a lower risk of major adverse cardiovascular events in humans after percutaneous coronary intervention for chronic coronary syndrome (HR, 0.32; 95% CI, 0.17-0.61).
“high-intensity statin therapy reduced the incidence of the primary outcome (HR, 0.32; 95% CI, 0.17-0.61; P<0.01)”
Humansafter percutaneous coronary intervention for chronic coronary syndromemedian follow-up of 2 yearsn = 716
Statins are linked with a lower risk of major adverse cardiovascular events in humans (patients with CKD and cardiomyopathy) (aOR 0.47, 95% CI 0.31-0.72).
“regular statin therapy remained independently associated with lower MACE risk, with the strongest benefit observed in the high-dose group (adjusted odds ratio = 0.47, 95% CI: 0.31-0.72, P = .001).”
Statins are associated with major adverse cardiovascular events in humans After ST-elevated myocardial infarction; fully adjusted analysis (12% higher chance of MACE with non-high intensity; reported interval 1.04–1.28).
“12% (1.04, 1.28) for patients on non-high statin intensity”
Statins lower the risk of major adverse cardiovascular events in humans (acute coronary syndrome patients undergoing percutaneous coronary intervention) (RR 0.55, 95% CI 0.46-0.67).
“Statin preloading significantly reduced MACE (RR 0.55, 95% CI 0.46-0.67; I 2 =0%)”
Atorvastatin lowers the risk of cardiovascular disease in humans (without clinical cardiovascular disease) (HR 0.70, 95% CI 0.61–0.82, P<0.001).
“a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group”
Human trialwithout clinical cardiovascular disease40 mg once daily5.9 yearsn = 9,971
Statins are linked with a lower risk of cardiovascular disease in humans (at SCORE2-OP of ~16% in adults aged 70-89 without diabetes) (HR=0.90 [0.84-0.96]).
“with a protective association becoming stable around a SCORE2-OP of 16% (HR=0.90 [0.84-0.96]).”
Humansat SCORE2-OP of ~16% in adults aged 70-89 without diabetesn = 167,360
Statins are linked with a lower risk of cardiovascular disease in humans (type 2 diabetes, emulated nested target trials) (HR 0.69 (95% CI 0.65–0.75)).
“a significant reduction in the incidence of CVDs (HR 0.69 (95% CI [0.65, 0.75]; p < 0.001))”
Statins are linked with a lower risk of cardiovascular disease in humans (primary prevention) (-20% new coronary events (HR 0.80, 95% CI 0.68-0.94, p = 0.008)).
“and a 20% reduction in new coronary events (HR 0.80; 95% CI: 0.68-0.94; p = 0.008).”
Humansprimary prevention4-year mean follow-upn = 15,745
Statins lower the risk of cardiovascular disease in individuals with migraines.
“Considering the increased cardiovascular risk in migraine sufferers compared with those without migraine, statins may play a beneficial role in both migraine management and cardiovascular risk reduction.”
Statins are linked with a higher risk of type 2 diabetes in humans (Elevated LDL-C; sustained statin therapy versus no statin therapy) (1 year: RD 2.2% (95% CI 1.6%, 3.0%), RR 2.13 (95% CI 1.80, 2.55); 5 years: RD 3.0% (95% CI 0.7%, 4.9%), RR 1.37 (95% CI 1.09, 1.62)).
“Among young adults with elevated LDL-C, sustained statin therapy increased the risk of diabetes during early follow-up, particularly among those with baseline HbA1c in the prediabetes range.”
HumansElevated LDL-C; sustained statin therapy versus no statin therapy1 and 5 years
British journal of hospital medicine (London, England : 2005)·
Simvastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (HR 1.15, 95% CI 1.06-1.20).
“simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”
Humansin patients with established ASCVD on moderate-intensity statin therapy
Pravastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (HR 1.19, 95% CI 1.02-1.38).
“pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”
Humansin patients with established ASCVD on moderate-intensity statin therapy
Rosuvastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (adjusted HR 1.07, 95% CI 1.01-1.14).
“rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”
Humansin patients with established ASCVD on moderate-intensity statin therapy
Rosuvastatin is associated with Alzheimer's disease in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.78, 95% CI 0.72–0.83; incidence 0.5% vs 0.6%; ARD -0.18%, 95% CI -0.22 to -0.15).
“Rosuvastatin use was also associated with lower risks of Alzheimer dementia”
Humanstype 2 diabetes; compared with atorvastatin users
Pravastatin lowers the risk of cardiovascular events in humans (Prediabetes with a history of myocardial infarction or unstable angina) (RR 0.81, 95% CI 0.70–0.95, p = 0.008).
“pravastatin significantly reduced cardiovascular events in patients with prediabetes with a history of myocardial infarction or unstable angina”
ReviewPrediabetes with a history of myocardial infarction or unstable angina
Atorvastatin lowers the risk of cardiovascular events in humans.
“Multiple large trials have shown that atorvastatin achieves concurrent control of lipids and inflammation, accompanied by reductions in cardiovascular events.”
Statins are associated with dementia in humans (All of Us Research Program discovery cohort; self-identified as White) (adjusted HR 2.22, 95% CI 2.02–2.44).
“Statin use was associated with significantly increased dementia risk in both cohorts (discovery: adjusted HR 2.22, 95% CI 2.02–2.44; replication: adjusted HR 2.54, 95% CI 1.98–3.33).”
HumansAll of Us Research Program discovery cohort; self-identified as White2006 through 2023n = 83,355
Statins are linked with a lower risk of dementia in humans within ≤ 1 year after type 2 diabetes diagnosis vs no statin within 5 years (-15% relative risk (95% CI 9%-21%)).
“early statin treatment was associated with 15% lower relative risk of dementia at 10 years (95% confidence interval: 9%-21%)”
Humanswithin ≤ 1 year after type 2 diabetes diagnosis vs no statin within 5 years10 years
Statins are linked with a lower risk of dementia in humans (stroke survivors) (HR 0.954, 95% CI 0.923-0.986).
“Over 5 years, incident dementia occurred in 6.6% of the high-intensity group (6,816/103,208) vs 6.9% of the low/moderate group (7,104/103,208) (HR 0.954, 95% CI 0.923-0.986; P = 0.005).”
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir·
Statins are associated with LDL cholesterol in humans (LDL-C reductions: 57.3% vs 38.2% at 3 months; 58.5% vs 42.9% at 9 months; 54.3% vs 46.7% at 15 months; all p<0.001).
“Patients receiving statin±ezetimibe showed greater LDL-C reduction compared to those not on combination therapy”
HumansConcomitant statins with or without ezetimibe during inclisiran treatment, compared with no combination therapy3, 9, and 15 months
Rosuvastatin is associated with rhabdomyolysis in humans (polypharmacy; adverse reaction classified as probable).
“We present a probable case of rosuvastatin-associated rhabdomyolysis causing stage 3 acute kidney injury requiring hemodialysis in an 87-year-old woman with polypharmacy”
Humanspolypharmacy; adverse reaction classified as probable20 mg/day20 daysfemales
Rosuvastatin is associated with rhabdomyolysis in humans During concomitant ticagrelor therapy after percutaneous coronary intervention.
“We present a case of severe rhabdomyolysis and AKI following initiation of high-intensity rosuvastatin therapy after percutaneous coronary intervention.”
HumansDuring concomitant ticagrelor therapy after percutaneous coronary intervention40 mg once dailyOne monthfemales
Statins are associated with cardiovascular mortality in humans (Cardiovascular death–free proportion 1.0 in patients and unaffected siblings versus 0.93 (95% CI 0.90–0.95) in affected parents; P=0.009).
“The cumulative cardiovascular death–free proportion was both 1.0 among patients with FH and their unaffected siblings, and 0.93”
HumansPatients with familial hypercholesterolemia treated from childhood compared with affected parents without childhood statin treatment
Arteriosclerosis, thrombosis, and vascular biology·
Atorvastatin is linked with a lower risk of cardiovascular mortality in humans (chemotherapy-treated cancer) (3.3% vs. 6.0%, HR 0.54 (95% CI 0.29–1.02)).
“trend toward lower cardiovascular mortality (3.3% vs. 6.0%; HR 0.54; 95% CI 0.29–1.02; p=0.058)”
Atorvastatin lowers the risk of cardiovascular and cerebrovascular events in humans (patients with carotid plaque; compared with no statin therapy) (22 events among 234 statin-treated patients versus 36 among 202 controls; log-rank P=0.0107).
“22 events occurred among 234 patients in the statin group and 36 among 202 patients in the control group”
Human trialpatients with carotid plaque; compared with no statin therapy20 mg dailyextended follow-up beyond 24 months through 2025
Statins are associated with noncalcified coronary plaque volume in humans (Post hoc analysis of asymptomatic, statin-naive, intermediate-risk individuals) (β = -9.83, SE = 1.64).
“alongside regression of noncalcified plaque (β = -9.83, SE = 1.64; P < 0.001)”
Human trialPost hoc analysis of asymptomatic, statin-naive, intermediate-risk individualscoronary plaque3 years57.1% mensn = 338
Statins are associated with high-density coronary calcium volume in humans (Post hoc analysis of asymptomatic, statin-naive, intermediate-risk individuals) (β = 0.79, SE = 0.24).
“and high-density (β = 0.79, SE = 0.24; P = 0.001) calcium, alongside regression of noncalcified plaque”
Human trialPost hoc analysis of asymptomatic, statin-naive, intermediate-risk individualscoronary plaque3 years57.1% mensn = 338
Statins are associated with intermediate-density coronary calcium volume in humans (Post hoc analysis of asymptomatic, statin-naive, intermediate-risk individuals) (β = 0.89, SE = 0.39).
“Statin treatment was associated with greater progression in intermediate-density (β = 0.89, SE = 0.39; P = 0.02)”
Human trialPost hoc analysis of asymptomatic, statin-naive, intermediate-risk individualscoronary plaque3 years57.1% mensn = 338
Simvastatin extends fly lifespan and pravastatin reduces senescence in human cells, with both results repeated by independent labs, although a finding shows shorter fly lifespan. Independent labs also report associations between statins and lower human mortality, while human studies report opposing dementia associations. Some papers declare ties to statin developers, which also sponsor trials.
Summary rewritten as its findings changed.
As it read before
Independent labs report longer fly lifespan with simvastatin and reduced senescence in human cells with pravastatin, but fly lifespan results also point the other way. A human cohort links statins with lower mortality after noncardiac surgery; other cohorts link them with higher diabetes incidence in normoglycemic people. Some human papers declare ties to companies developing statins.
Summary rewritten as its findings changed.
As it read before
Independent labs link statins with lower human mortality and simvastatin with longer fly lifespan, but fly lifespan and human dementia results disagree. Of registered trials, 108 concern aging; 749 across all uses ended over a year ago without posted results or citing papers. Authors declare developer ties, and developers sponsor 391 trials across all uses.
Summary rewritten as its findings changed.
As it read before
Independent labs report longer fly lifespan with simvastatin and lower human mortality with statins, but other studies report shorter fly lifespan or no human mortality effect. There are 101 aging-related registered trials; 749 trials across all uses ended over a year ago without posted results or citing papers. Developers sponsor 394 trials across uses, and 20 human papers declare developer ties.
Summary rewritten as its findings changed.
As it read before
Simvastatin extends fly lifespan across independent labs but not in a worm study; independent labs also associate statin use with lower human mortality. There are 91 aging-related trials; across all uses, 730 trials ended over a year ago without posted results or citing papers. Developer companies sponsor 378 trials across all uses.
Estimated 10-year dementia risks were 9.4% with statins and 9.6% without them in an analysis of veterans’ health records.Estimated 10-year dementia risks were 9.4% with statins and 9.6% without them in an analysis of veterans’ health records.